A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With or Without Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Gemcitabine (Primary) ; Ubidecarenone (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Berg Pharma
- 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 11 Sep 2017 Results presented at the European Society for Medical Oncology (ESMO) 2017 Congress, according to a BERG media release.
- 10 Jun 2017 Biomarkers information updated